Hodgkin Lymphoma Clinical Trials

52 recruiting

Hodgkin Lymphoma Trials at a Glance

224 actively recruiting trials for hodgkin lymphoma are listed on ClinicalTrialsFinder across 6 cities in 43 countries. The largest study group is Phase 2 with 113 trials, with the heaviest enrollment activity in Houston, New York, and Duarte. Lead sponsors running hodgkin lymphoma studies include City of Hope Medical Center, Mayo Clinic, and Baylor College of Medicine.

Browse hodgkin lymphoma trials by phase

Treatments under study

About Hodgkin Lymphoma Clinical Trials

Looking for clinical trials for Hodgkin Lymphoma? There are currently 52 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hodgkin Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hodgkin Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 224 trials

Recruiting
Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
National Cancer Institute (NCI)1,875 enrolled403 locationsNCT05675410
Recruiting
Phase 2

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

Hodgkin Lymphoma
St. Petersburg State Pavlov Medical University83 enrolled4 locationsNCT06812858
Recruiting
Phase 1

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma+1 more
AstraZeneca227 enrolled27 locationsNCT04594642
Recruiting
Phase 1

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Non-Hodgkin LymphomaLymphoma
National Cancer Institute (NCI)55 enrolled1 locationNCT04739813
Recruiting
Phase 1Phase 2

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Recurrent T-Cell Non-Hodgkin LymphomaRefractory T-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center50 enrolled1 locationNCT07225985
Recruiting
Phase 2

Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma

Classic Hodgkin Lymphoma
Sun Yat-sen University108 enrolled1 locationNCT05949931
Recruiting
Phase 1Phase 2

Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center30 enrolled1 locationNCT07283679
Recruiting
Phase 1

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Non-Hodgkin LymphomaPlasmablastic LymphomaBurkitt Lymphoma+2 more
National Cancer Institute (NCI)25 enrolled1 locationNCT05389423
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Hereditary Breast and Ovarian CancerHodgkin LymphomaAdrenocortical Carcinoma+30 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting

Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors

Hodgkin Lymphoma, Adult
St. Jude Children's Research Hospital100 enrolled1 locationNCT06421987
Recruiting
Phase 2

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRefractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified+5 more
City of Hope Medical Center43 enrolled3 locationsNCT07365306
Recruiting
Not Applicable

Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma

Hodgkin Lymphoma
St. Jude Children's Research Hospital20 enrolled1 locationNCT07222345
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled127 locationsNCT05006716
Recruiting
Phase 2

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

Classic Hodgkin Lymphoma
City of Hope Medical Center23 enrolled1 locationNCT07275216
Recruiting
Phase 2

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center71 enrolled8 locationsNCT06377566
Recruiting
Phase 2

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin LymphomaRecurrent Indolent Non-Hodgkin LymphomaRefractory Indolent Non-Hodgkin Lymphoma+2 more
Mayo Clinic112 enrolled7 locationsNCT06386315
Recruiting
Phase 1Phase 2

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Non-Hodgkin LymphomaLymphoma
National Cancer Institute (NCI)155 enrolled1 locationNCT03223610
Recruiting
Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma
Hoffmann-La Roche121 enrolled26 locationsNCT05169515
Recruiting
Phase 1Phase 2

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

Hodgkin LymphomaNon-Hodgkin LymphomaLymphoma+4 more
AstraZeneca161 enrolled33 locationsNCT06137144
Recruiting
Phase 1Phase 2

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

B-cell Non Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver45 enrolled1 locationNCT04544592